Cui Su-nan, Wang Ming-ming
Ji'nan Infectious Disease Hospital, Ji'nan 250021, China.
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Dec;19(4):395-7.
To evaluate the efficacy of alpha-2b interferon alone or combined with alpha1-thymosin in treatment of patients with chronic hepatitis B (CHB) resistant to lamivudine.
Sixty six patients with CHB resistant to lamivudine were enrolled and randomized into treatment group A, treatment group B and control group. In the treatment group A 26 cases, after giving interferon-alpha alone for 1 month, lamivudine was withdrawn and continuously treated with interferon-alpha for 5 months. In the treatment group B 10 cases, after treatment with interferon-alpha and thymosin-alpha1 for 1 month, lamivudine was withdrawn and continuously treated with interferon-alpha and thymosin-alpha1 for 5 months. In control group (30 cases), after lamivudine was directly withdrawn, no anti-virus drug was given. Hepatic function tests and serum virological index were detected at regular intervals in all patients.
Normalization rate of hepatic function, HBV DNA seroconversion rate and HBeAg/HBeAb seroconversion rate in two treatment groups were significantly higher than those in control group.
The study suggested that interferon-alpha alone or combined with thymosin-alpha1 in treatment of patients with chronic hepatitis B resistant to lamivudine showed a beneficial effect.
评估单用α-2b干扰素或联合α1-胸腺肽治疗对拉米夫定耐药的慢性乙型肝炎（CHB）患者的疗效。
纳入66例对拉米夫定耐药的CHB患者，随机分为治疗组A、治疗组B和对照组。治疗组A共26例，单用α-干扰素1个月后停用拉米夫定，继续用α-干扰素治疗5个月。治疗组B共10例，用α-干扰素和α1-胸腺肽治疗1个月后停用拉米夫定，继续用α-干扰素和α1-胸腺肽治疗5个月。对照组（30例）直接停用拉米夫定，未给予抗病毒药物。定期检测所有患者的肝功能和血清病毒学指标。
两个治疗组的肝功能正常化率、HBV DNA血清学转换率和HBeAg/HBeAb血清学转换率均显著高于对照组。
该研究提示，单用α-干扰素或联合α1-胸腺肽治疗对拉米夫定耐药的慢性乙型肝炎患者有有益作用。
